T HE SKELETON IS continuously remodeled through a regulated process that involves a complex network of systemic and local factors, activating multiple signaling pathways. Indeed, all skeletal diseases can be linked to the local or systemic dysregulation of this process. Two cell lineages are involved in bone remodeling: the hematopoietic bone-resorbing osteoclasts and the bone-forming mesenchymal osteoblasts and osteocytes (1) . Two important mesenchymal cell gene products are required for osteoclast differentiation, macrophage colony-stimulating factor (Csf1/M-CSF) and receptor activator of nuclear factor-B ligand (Tnfsf11/RANKL) and are secreted by the osteoblast (2, 3) . RANKL stimulates osteoclast maturation and function through interaction with its receptor, RANK, expressed at the surface of osteoclasts. In addition, osteoblast-secreted osteoprotegerin (OPG) acts as a decoy receptor inhibiting the interaction between RANKL and RANK (4) . Conversely, gene products derived from the osteoclast and/or from the bone matrix during bone resorption can modulate osteoblasts (5) (6) (7) .
In the adult, bone formation by mesenchymal stem cellderived osteoblasts occurs in the context of bone remodeling and is counterbalanced by the bone-resorbing activity of osteoclasts. It is the overall balance between these two activities that allows bone mass to accrue during establishment of peak bone mass in children and young adults and to be maintained throughout life in adults. In contrast, it is an imbalance between bone resorption and bone formation that leads to bone loss and osteoporosis in older patients.
If current therapies can prevent bone loss through antiresorptive activity, they cannot activate bone formation, with the exception of PTH. Thus, understanding the mechanisms that regulate bone formation is one of the highest priorities in both academic and pharmaceutical research on the skeleton and a new frontier in the treatment of osteoporosis, possibly allowing treatment to rebuild bone mass and architecture to levels where the biomechanical function of the skeleton can safely be performed. The exploration of the mechanisms by which the formation of bone is regulated during embryogenesis has clearly established a role for members of the hedgehog family of proteins and their receptors (smoothened and patch) as well as for bone morphogenetic proteins (BMPs) and their receptors (8 -11) . Several marker genes of the osteoblast lineage are now identified, and the picture that emerges is that of a cascade of signaling pathways each of which activates the expression of a few genes characteristic of the osteoblast lineage as well as the expression of the ligand for the following signaling cascade, ultimately leading to the expression of the full set of genes characteristic of a mature, bone matrix-secreting osteoblast. In several instances, loss-offunction mutations in humans lead to a characteristic genetic skeletal syndrome mimicked by gene deletion in mice. Deletion of Runx2 leads to a complete lack of bone formation in mice and to craniofacial dysostosis in heterozygous humans (12) (13) (14) ; deletion of osterix leads to an arrest along the osteoblast differentiation pathway and several skeletal abnormalities in mice (15). Although in humans, RUNX2 mutations are clearly linked to cleidocranial dysplasia (14, 16) , the link between these genes and the regulation of bone mass and/or the susceptibility to osteoporosis is still unclear, despite some recent reports (17, 18) .
In what constitutes the most important breakthrough in this field in recent years, a clear link has now been established between low-density lipoprotein receptor (LDLR)-related protein 5 (LRP5), a coreceptor for Wnts, and bone mass in humans and in mice. Loss of function in LRP5 leads to the osteoporosis pseudo-glioma syndrome (OPPG), with extremely low bone mass, whereas gain of function leads to the high bone mass (HBM) phenotype in humans (19 -21). In addition, deletion mutations in the gene encoding sclerostin (Sost), an endogenous inhibitor of the Wnt pathway, also lead to osteosclerotic phenotypes (sclerosteosis, van Buchem syndrome) (22-24). Before these findings, aberrant Wnt signaling in adult life was mainly linked to tumor progression (25). These important observations have opened a whole new field of investigation both in terms of understanding the mechanism that regulate osteoblasts and their activity and in terms of drug discovery, in the hope to target one component of the Wnt signaling pathway and increase bone mass in osteoporotic patients.
The goal of this review is to briefly discuss our current understanding of Wnt signaling in bone and how it affects drug discovery.
Wnt Signaling: Canonical Pathway
The Wnt signaling cascade is triggered upon binding of members of the Wnt family proteins (over a dozen distinct Wnts have been identified; see http://www.stanford.edu/ ϳrnusse/wntwindow.html) to a coreceptor complex, including frizzled (Fz, a G protein-coupled receptor-like protein) and LRP5 or -6. The signal is transmitted through recruitment of several proteins to the C-terminal intracellular moieties of the activated Fz and LRP5/6 coreceptors. From this point, disheveled (Dvl) is recruited and posttranslationally modified, and depending on the specific nature of the Wnt and of the Fz that are complexed with LRP5/6, three independent pathways can be activated: canonical, noncanonical, or Ca 2ϩ . In this review, and because all the data generated so far indicate that this is the pathway that regulates bone formation downstream of LRP5/6, we will focus our discussion only on the canonical pathway (for more details see review, Ref. 25).
The Wnt canonical signaling pathway relies mainly on the stabilization of cytosolic ␤-catenin. In the absence of Wnt proteins, ␤-catenin is phosphorylated by several kinases, mainly glycogen synthase kinase 3␤ (GSK-3␤) but also casein kinase 1, and targeted to ubiquitination and degradation by the proteasomal machinery. Wnt binding to its receptor complex results in the inhibition of GSK-3␤ activity. This inhibition mediates the prevention of ␤-catenin degradation, leading to an accumulation of ␤-catenin in the cytoplasm. Upon reaching a certain concentration level, ␤-catenin translocates to the nucleus where it associates with the Tcf/Lef family of transcription factors to regulate the expression of canonical Wnt target genes (Fig. 1) .
Given the importance of this signaling pathway in the control of numerous cellular functions, several fine-tuning regulatory systems have evolved at the extracellular, cytosolic as well as nuclear levels. (Sost) proteins that bind to and inactivate signaling from LRP5/6 receptors. Cytosolic Wnt signaling inhibitors are also found intracellularly, the most predominant ones being GSK-3␤ (described above), the scaffolding protein axin and the tumor suppressor adenomatous polyposis coli. All these proteins are included in the ␤-catenin phosphorylation complex, which leads to ␤-catenin degradation. Finally, in the nucleus, the ␤-catenin/Tcf complex is also subject to tight control of either its transcriptional activity or its nuclear localization. For instance, Ctnnbip1/Icat or Cby/Chibby have been shown bind to ␤-catenin, and either inhibit its interaction with Tcf or translocate it to the cytoplasm, respectively. Alternatively, transcriptional repressors such as Groucho are capable of binding to a specific domain of Tcf, thus neutralizing its activity, downstream of ␤-catenin.
Thus, the fact that Wnt canonical signaling requires LRP5/6 activity and that there are a number of extracellular agonists and antagonists as well as intracellular enzymatic regulators offers significant opportunities for therapeutic regulation. For the skeleton, the fact that LRP5 gain-or lossof-function mutations have been shown to regulate bone mass in humans and that mutations in at least one LRP5 natural antagonist, sclerostin, is linked to two osteosclerotic phenotypes (sclerosteosis and van Buchem syndrome) has focused the attention on LRP5 and its signaling activity.
Canonical Wnt Receptor LRP5/6: Structure, Function, and Regulation LRP5/6 belong to the LDLR family, which are cell surface proteins capable of binding and internalizing ligands through receptor-mediated endocytosis. Unlike other members of the LDLR family, LRP5/6 do not contain an internalization signal sequence required for endocytosis but have been shown to bind Wnt proteins and mediate canonical Wnt signaling (26).
Lrp5 and Lrp6 encode 1615-and 1613-amino-acid transmembrane proteins, with 71% homology between them. The extracellular domain of both receptors is mainly composed of N-terminal 6xYWTD repeats and (EGF)-like sequence, this repeated four times then followed by a LDLR-like ligandbinding domain. Crystal structure analysis has revealed that the YWTD repeats forms a six-bladed b-propeller module (27). The first module was shown to bind Wnt and Sost proteins, whereas the third one binds and mediates Dkk inhibition.
The cytoplasmic domain of LRP5/6 is also very distinct from other LDLRs. First, the classical NPXY motif found in LDLRs is absent in LRP5/6. Second, the LRP5/6 cytoplasmic tail is particularly rich in prolines and serines and several PPP(S/T)P motifs are essential for LRP5/6-mediated Wnt signaling. It has been shown that Wnt binding to LRP5/6 results in the dual phosphorylation of PPP(S/T)P motifs by CKI and or GSK-3␤, resulting in the recruitment of axin to the membrane, an event that is crucial to activate downstream signaling (28, 29). The cytoplasmic tail of LRP5/6 recruits not only axin but also other proteins such as frequently rearranged in advanced T-cell lymphomas (Frat1) and microtubule-actin cross-linking factor 1 (MACF1) (30, 31). These interactions are required to disrupt the GSK-3␤/ APC/axin/␤-catenin protein complex and thereby prevent the phosphorylation and degradation of ␤-catenin, leading to its cytoplasmic stabilization.
Although LRP5 and LRP6 are undistinguishable when compared for their capacity to transduce Wnt signaling, genetic investigations demonstrate at least one difference between these two close receptors. LRP6, but not LRP5, is required during embryonic development. Actually, Lrp6-deficient mice die at birth, whereas Lrp5-deficient mice are viable, possibly due to redundant functions with Lrp6 (32). This clearly demonstrates that, although highly redundant, LRP5 and -6 have some distinct properties. More studies are required to determine whether LRP6 and LRP5 interact with a distinct subset of Wnt ligands or whether they act as receptors for other ligands engaging distinct signaling pathway. Interestingly, LRP6 has been recently shown to mediate the internalization and lethality of anthrax toxin, indicating that such receptors may be involved in distinct signaling pathways (33).
Noteworthy is the fact that if several families have been identified with mutations of LRP5 leading to skeletal alterations, whether HBM or OPPG, or with Sost mutations, leading to osteosclerosis, mutations in LRP6 have not yet been reported to be linked to skeletal defects. Thus, it seems to be that LRP5 and the canonical Wnt signaling are the keys to the regulation of bone mass in humans.
Involvement of Canonical Wnt Signaling in Bone Metabolism
Key data as to the importance of the Wnt signaling pathway in the control of bone mass were provided by the identification of mutations in the Wnt coreceptor LRP5 gene inducing either the OPPG or the hereditary HBM trait in humans (19 -21). OPPG is a rare autosomal recessive disorder affecting bone and vision associated with loss-of function mutations in the LRP5 gene (20). OPPG patients display a very low bone mass and are prone to develop skeletal fractures and deformities. In contrast, gain-of-function mutations of LRP5 have been found to be associated with increased bone density in the autosomal dominant HBM trait (19, 21, 34). Additional independent epidemiological studies have linked sequence variants in the LRP5 gene with differences in bone mineral density (BMD) and/or fracture risk (35) (36) (37) (38) (39) .
These findings were further supported by genetic manipulation of Lrp5 gene in mice. Indeed, knocking out Lrp5 or introducing gain-of-function mutations produced similar phenotypes to those observed, respectively, in OPPG and HBM (32, 40, 41) . Several other mouse models support the notion that activating Wnt signaling leads to increased bone mass. For instance, overexpression of Wnt10b in adipose dation and pathway signaling inactivation. B, After Wnt binding to its LRP5/6 and Fz coreceptors, GSK-3␤ is inactivated. ␤-Catenin is then stabilized and accumulates in the cytoplasm. ␤-Catenin will consequently translocate into the nucleus where it affects gene expression. C, The secreted Dkk proteins bridge LRP5/6 and the transmembrane protein Krm. This results in the LRP5/6 membrane depletion by internalizing the receptors. As a consequence, Wnt signaling is inhibited. Sclerostin (Sost) also inhibits Wnt signaling through binding to LRP5/6, but its activity is independent of Krm proteins. 
tissue results in increased bone mass and strength and induces a resistance to aging or hormonal-related bone loss (42) . Furthermore, inactivating or reducing the expression of Wnt antagonists such as Sfrp1, Apc, or Dkk1 markedly increased trabecular bone mass in adult mice (42) (43) (44) (45) (46) . On the other hand, overexpressing Wnt antagonists such as Ctgf, Wif1, and Dkk1 decreases bone density (45, (47) (48) (49) . Taken together, all these reports establish unequivocally the critical role of Wnt and LRP5 in the regulation of bone mass in humans and in rodents. Interestingly, loss-or gain-of-function mutations affecting LRP5 either in humans or in mice alter bone formation without affecting the resorption parameters. This indicates that osteoblasts are indeed the main cellular targets of Wnt effects in bone. It was then demonstrated that ␤-catenin is essential in determining whether mesenchymal progenitors become osteoblasts or chondrocytes (50 -52) , indicating that Wnt signaling can affect osteoblast commitment. An additional mechanism by which Wnt may control osteoblast commitment is by blocking adipogenesis via the inhibition of the adipogenic transcription factors CCAAT/enhancer-binding protein-␣ (C/EBP␣) and peroxisome proliferator-activated receptor-␥ (PPAR␥) as demonstrated in vivo in Wnt10b transgenic mice (42) or in vitro (53) , although a direct inverse relationship between the pools of these two mesenchymal lineages has never been firmly established. Taken together, these results suggest that Wnt signaling can determine the cell fate of mesenchymal precursors (Fig. 2) .
In addition to regulating osteoblast commitment, Wnt/␤-catenin signaling is also suspected of affecting osteoblast proliferation. Lrp5 Ϫ/Ϫ mice show reduced osteoblast proliferation (32) and, although osteoblast proliferation has not been directly measured, an Lrp5 (G171V) transgenic model displays a significant increase in osteoblast number and a reduced number of apoptotic osteoblasts and osteocytes in calvaria (41) .
But the main effect of the canonical Wnt signaling may well be in osteoblast differentiation and function. First, the expression of several key components of Wnt signaling is regulated during osteoblast differentiation (54 -56) . Among those, Wnt signaling antagonists, including Sfrp2, Wif1, Dkk1, or FrzB, are strongly up-regulated during the late phase of osteoblast differentiation, suggesting that a negative Wnt feedback loop may control the last steps of osteoblast maturation. Second, Lrp5-deficient mice display a decrease in bone matrix deposition (32), and osteoblasts overexpressing a constitutively active mutant of ␤-catenin constitutive show an increase of collagens type Ia1 and -a2 gene expression (44) . Thus, Wnt canonical signaling controls osteoblasts at different levels: commitment, proliferation/apoptosis, and function.
As discussed earlier, based on the data in Lrp5 mutants, one could conclude that the Wnt canonical pathway does not regulate osteoclasts. However, evidence in vitro and in vivo indicates that Wnt regulates the expression of osteoprotegerin, the decoy RANK receptor that inhibits osteoclast differentiation by interacting with RANKL. First, ␤-catenindeficient osteoblasts exhibit an elevated expression of
Role of Wnt/␤-catenin signaling in determining the cell fate from mesenchymal progenitor cells. Wnt signaling plays a dual role in regulating chrondrocytic differentiation. The Wnt canonical pathway represses chondrocyte differentiation from progenitor cells, whereas it is required for chondrocyte hypertrophy. Wnt pathway activation also inhibits adipocyte differentiation and promotes osteoblast cell lineages by controlling proliferation, maturation, and terminal differentiation. Differentiated osteoblasts or osteocytes produce Wnt inhibitors such as Dkk1 and sclerostin as a negative feedback control of osteoblast differentiation and/or function. Committed osteoblasts produce OPG to increase the OPG/RANKL ratio, thus decreasing osteoclast differentiation and activation.
RANKL and a diminished expression of OPG, whereas Apcdeficient osteoblasts display a decreased expression of RANKL and increased OPG (44, 45) . This may explain why the osteoblast-selective deficiency of ␤-catenin in mice affects bone resorption rather than bone formation. Second, Dkk2 deficiency in mice results in osteopenia associated with reduced osteoblast differentiation and enhanced osteoclast function (57) . The effect on osteoclasts in this model most likely results from an increase in osteoclast-activating cytokines, including macrophage colony-stimulating factor and RANKL. Finally, a recent report by Diarra et al. (58) clearly demonstrates a cross-talk between the bone-anabolic Wnt and the bone-catabolic RANKL pathway. All these data strongly suggest that Wnt signaling indirectly controls osteoclast differentiation via its effect on osteoblasts. These observations on the regulation of the RANKL/OPG ratio might be relevant not only to osteoporosis but also in the development of multiple myeloma osteolytic lesions and joint diseases such as rheumatoid arthritis and osteoarthritis (58, 59) .
Targeting the LRP5/Wnt Signaling Pathway to Treat Bone Diseases
The logical consequence of the tremendous accumulation of knowledge on the role of the LRP5/Wnt signaling pathway in regulating bone formation, all generated in only the last 6 yr, has been to trigger a significant effort by the pharmaceutical and biotech industry to discover and develop therapeutic products that would be anabolic to bone, i.e. increase bone formation in osteoporotic and other osteopenic patients. Although there were, and still are, significant worries about activating the Wnt signaling pathway in a systemic manner, possibly leading to tumorigenesis (see Ref. 25 for review), the recent observations on the bone-specific distribution of two key natural inhibitors of LRP5/Wnt, specifically Dkk1 and Sost, have been reassuring for the targeting of these two antagonists to increase bone formation.
GSK-3␤
Among the intracellular elements of the Wnt signaling cascade, one of the most amenable to drug targeting is the enzyme GSK-3␤. It is a multifunctional serine/threonine kinase found in all eukaryotes. However, the enzyme is a key regulator of numerous signaling pathways, including cellular responses to Wnt, receptor tyrosine kinases, and G protein-coupled receptors and is involved in a wide range of cellular processes, ranging from glycogen metabolism to cell cycle regulation and proliferation (60) , making it a far less desirable target than Dkk1 and Sost. GSK-3 is unusual in that it is normally active in cells and is primarily regulated through inhibition of its activity. Another peculiarity compared with other protein kinases is its preference for primed substrates, that is, substrates previously phosphorylated by another kinase (61) .
Because increased GSK-3 activity may be linked to pathology in diseases such as Alzheimer's disease and noninsulin-dependent diabetes, several GSK-3 inhibitors have been developed. Treatment with GSK-3␤ inhibitors, including lithium and 6-bromo-indirubin-3Ј-oxime, enhance bone formation and increase bone mass in several mouse models (40) . Lithium has been used safely and effectively for over a half-century in the treatment of bipolar disease. Interestingly, a separate study that addressed the effects of lithium on fracture risk using a case-control study design revealed that lithium treatment was associated with a decreased risk of fractures, thus potentially pointing at bone-anabolic properties in humans (62) . In an independent study, an orally bioavailable dual GSK-3␣/␤ inhibitor, LY603281-31-8, was tested for its activity in bone mass in ovariectomized rats. GSK-3 inhibitor increased expression of several bone-specific genes including collagen-␣1 (I) and -␣1 (V), biglycan, osteonectin, and runx-2 (63). Furthermore, significant increase in bone mineral content and BMD was observed in cancellous and cortical bone of ovariectomized rats treated with GSK-3 inhibitor. This was associated with improved mechanical properties of lumbar vertebrae (63) . All these data clearly indicate that orally available small-molecule GSK-3 inhibitors induce osteoblast differentiation and bone formation, increasing bone mass and strength in vivo, consistent with a role for the canonical Wnt pathway in osteogenesis. The challenge will, however, be whether a specific molecule or dosage will allow the restriction of the effects of these inhibitors to the skeleton.
Targeting Endogenous Wnt Inhibitors in Bone
Indeed, the specific targeting of Wnt activation to the skeleton, extremely difficult to achieve with small molecules targeting LRP5/6, Fz, or the enzymes that are regulated intracellularly downstream of these receptors (see GSK-3␤), may be achievable by targeting Dkk1 or Sost with humanized monoclonal antibodies. This prediction is based upon the fact that in the adult mouse skeleton, these two proteins are essentially restricted to osteoblasts and/or osteocytes (47, 64) . Thus, systemic administration of antagonists to Dkk1 or Sost may possibly affect only the skeleton, favoring endogenous Wnt signaling and increasing bone formation without affecting Wnt signaling in other organs.
Dkk Proteins
Dkk genes include four evolutionary conserved members (Dkk1-4) that encode for a secreted glycoprotein of 255-235 amino acids. They share two conserved cysteine-rich domains at the N and C termini called, respectively, Cys-1 and Cys-2, and each displays a specific spacing sequence (Fig. 3) . It is now well established that Dkk1, -2, and -4 either physically or functionally interact with LRP5 and LRP6 and affect Wnt signaling. Dkk1 binds to the C-terminal domains 3 and 4 of LRP5/6 receptors (65-70). The Cys-2 domain of Dkk proteins is sufficient to mediate binding to LRP6, and mutation of the conserved Cys220 residue abolishes the interaction (69) . In addition, a 21-amino-acid synthetic peptide (L218-Ser204 or Cys233-Cys253) derived from the Dkk1 Cys-2 domain displays high binding affinity for LRP6 and is sufficient to inhibit Wnt signaling (71) .
In addition to LRP5/6, Dkk proteins bind to another single-pass transmembrane receptor family, Kremen-1 (Krm1) and Krm2 (72) (73) (74) . Both Krms bind Dkk1 and Dkk2 with high affinity (nanomolar range). Like for LRP5/6, it is the Cys-2 domain that mediates binding to Krm1/2 (74). Although Dkk1, -2, and -4 are capable of binding LRP5/6 in the absence of Krm, Krm1/2 potentiate the capacity of Dkks to inhibit Wnt signaling (73) . In fact, in the presence of Krms, a Dkk/ LRP/Krm protein complex forms and is rapidly endocytosed, resulting in the removal of LRP5/6 receptors from the cell's membrane. Thus, Dkk binding to LRP5/6 inhibits canonical Wnt signaling and Dkk/LRP5/6 complexes with Krms, depleting the cell membrane of LRP receptors and resulting in a greater and more prolonged inhibition of Wnt signaling (Fig. 1) .
Dkk3 functionally falls apart from the other Dkk proteins. In fact, Dkk3 is unable to inhibit Wnt signaling (75) , and unlike Dkk1-or Dkk2-deficient mice (see bellow), Dkk3 knockout animals do not display bone phenotype (76) . Dkk proteins play a distinct role during embryogenesis; for instance, Dkk1-deficient mice are not viable because of lack of lack head structures anterior of the midbrain, whereas Dkk2 and Dkk3 knockouts are viable and fertile (57, 76, 77) .
Several lines of evidence demonstrate the involvement of Dkk1 in the regulation of bone formation and establish the validity of this target for therapeutic intervention for bone anabolism. Whereas reduced expression of Dkk1 in mice haploinsufficient for the Dkk1 gene results in a HBM phenotype, increased expression in transgenic mice leads to osteopenia (46, 47) . This suggests that controlling Dkk1 levels or binding capacity could be used as a therapeutic strategy to increase bone mass in various bone diseases, such as postmenopausal or aging osteoporosis, osteogenesis imperfecta, or cancer-induced bone loss (this review and Refs. 59 and 78). As a matter of fact, Dkk1 antisense oligonucleotide in rats has been shown to prevent the effects of ovariectomy on mineral content, mineral density, and peak load of femurs (79) . Dkk1 antisense oligonucleotide treatment affected bone metabolism by increasing osteoblast numbers and also by reducing RANKL expression, ultimately decreasing osteoclastogenesis.
Numerous tumors involve terminally differentiated plasma cells that home to the bone marrow, where they proliferate, leading to an osteolytic bone lesion (80) . The expression of Dkk1 in plasma cells and the serum level of Dkk1 are positively correlated with the presence of bone lesions in patients with multiple myeloma (59) . Dkk1 activity was also found to be associated with the osteolytic potential of other cancer cells such as the prostate cancer line PC-3 (81) . A recent report from Shaughnessy and colleagues (82) provided the proof of concept that anti-Dkk1 therapy may be an effective adjunct in the clinical management of multiple myeloma-associated bone disease. Blocking Dkk1 activity by means of monoclonal neutralizing antibody in myelomatous bones reduces osteolytic bone resorption, increases bone formation, and helps control multiple myeloma growth. The bone-anabolic effect of anti-Dkk1 was associated with reduced multiple myeloma burden (P Ͻ 0.04). Interestingly, anti-Dkk1 also displayed a bone-anabolic activity as shown by a significant increase in BMD in the femur of nonmyelomatous mice (82) . Thus, these studies confirmed that antiDkk1 treatment affects osteoblast activity and indirectly reduces osteoclast activity.
Wnt signaling is also essential in determining whether mesenchymal progenitors will become osteoblasts or chondrocytes (for review see Ref. 83) . Until recently, it was thought that these mechanisms were involved only in development. However, a very recent study has demonstrated the involvement of Dkk1 in the destructive joint process in TNF-induced arthritis (58) , suggesting that inflammation induces Dkk1 expression and that inhibition of Wnt signaling contributes to joint destruction.
Dkks are therefore a very attractive target for the pharmaceutical industry with applications in osteoporosis and cancer-induced bone loss as well as joint diseases. As discussed below, the key issue will remain the possibility of undesired effects outside of the skeleton.
Sclerostin (Sost)
The Sost gene product sclerostin is also a secreted Wnt antagonist, which shares homology with another Wnt an- The most important recent finding is that sclerostin is almost exclusively expressed in osteocytes (64) . It is thought that these cells, embedded in the mineralized matrix of the bone, are the main mechanosensors in bone, participating in the regulation of bone formation and the determination of bone mass and shape through bone remodeling. Although the precise physiological role of sclerostin in osteocytes is not fully elucidated, recent data have indicated that sclerostin expression decreases in the presence of mechanical loading, and also upon PTH treatment, possibly locally relieving endogenous Wnt inhibition and activating bone formation (88 -91) .
Sclerostin-neutralizing monoclonal antibodies have been developed and show bone-anabolic activity in mice and rats (92) . In nonhuman primates, this neutralizing antibody showed a favorable pharmacokinetic profile and displayed significant anabolic activity (93) , making it a serious candidate to enter clinical studies in the near future.
Summary and Future Challenges
One important conclusion of the observations made with all the different in vivo models described above, is that activating Wnt/␤-catenin signaling positively affects bone formation, whereas deletion or down-regulation of genes encoding for agonists of the Wnt cascade results in osteopenia. Better understanding of this pathway makes it amenable to pharmacological intervention at many levels. Current therapies for osteoporosis are almost exclusively based on an antiresorptive approach, but there is a real medical need for alternative therapies based on the stimulation of the anabolic pathways in bone, the only available anabolic agent being injectable PTH. As molecules emerge from current drug discovery activities targeting the Wnt signaling pathway at different levels, investigating the tumor potential and toxicity to other tissues will be crucial. Treatment of chronic disorder such as osteoporosis requires a very stringent safety profile, and given the known involvement of Wnt signaling in certain cancer, the challenge for molecules modulating the Wnt pathway is to target bone as specifically as possible. The most appropriate way to prevent systemic stimulation of the Wnt pathway by pharmacological agents is to target Wnt bonespecific genes. From this perspective, sclerostin, and possibly Dkk1, seem to fulfill the criterion of bone-specific antagonists. Of note, however, are the facts that HBM and lithiumtreated patients have not been reported to have an increased frequency of tumors, and Dkk1 ϩ/Ϫ mice, in which the Wnt pathway is activated and bone formation increased, have not exhibited tumors over the 2 yr since they have been generated (unpublished observation).
The formidable progress made in the past 5 yr in understanding the role of Wnt signaling in bone will undoubtedly lead to the development of therapeutics activating the Wnt pathway, possibly only in the skeleton. Indeed, several compounds are in early-stage discovery or just reaching phase I clinical trials. Inhibiting sclerostin by means of neutralizing antibodies is probably the most advanced program, but Dkk1 antibodies are not far behind.
